Blood based tumour monitoring: precise, early, reliable

cancertrack monitoring is a blood-based ctDNA test for monitoring solid tumours. The analysis detects tumour-associated genetic changes with high sensitivity and specificity and enables continuous, minimally invasive monitoring of tumour dynamics.

Repeated quantitative and qualitative analysis of circulating tumour DNA allows early detection of recurrence – often even before imaging diagnostics. In addition, the test enables the identification of clinically relevant mutations, which supports targeted therapy adjustment.

Features of cancertrack

  • Detection of circulating tumour DNA (ctDNA) that is released into the patient's blood by cancer cells
  • If requested: additional quantification of circulating tumour cells (CTCs)
  • Detection of gene fusions via RNA
  • Monitoring of metastases and tumours that are not detected by imaging
  • Limit of detection: 0.1% MAF (Minor Allele Frequency)
  • Real-time adjustment of medication based on test results

cancertrack is suitable for

... every patient who is under treatment for cancer.

... every person who has been diagnosed with cancer, as a supplement to conventional biopsy and imaging.

... every patient who is in remission / a cancer survivor and needs monitoring.

Monitoring of the cancer

At best, the treatment is always one step ahead of the cancer disease. cancertrack monitoring ensures real-time monitoring of tumour evolution – for oncological care that is always one step ahead of the disease. Clinically relevant mutations can be identified and the treatment can be customised accordingly.

Advantages of cancertrack monitoring

  • ctDNA & CTC*

    Information on cancer activity

  • ctDNA

    Molecular dynamics in real-time

  • ctDNA & CTC*

    Indications for therapy success

  • ctDNA

    Quantitative markers for longitudinal monitoring

Sample case: Invasive ductal breast carcinoma

Both ctDNA and CTCs proved to be clinically relevant sources of information in this case.
A therapy-relevant mutation was detected not only in the tumour tissue, but also in the blood. The positive course of therapy was consistently reflected in the dynamics of both markers – ctDNA and CTCs. cancertrack monitoring is therefore a multifunctional and practical tool in cancer therapy.

View sample case (PDF)

FAQ

Why is early detection of molecular dynamics of cancer critical?

The molecular evolution of the tumour, including tumour size and molecular diversification, is a continuous process that can progress at high speed. Therefore, early detection of recurrence or drug resistance is essential to keep the cancer under control.

How frequently is it necessary to perform the test?

cancertrack should ideally be performed at every important milestone in the fight against cancer and especially when the tumour has disappeared from conventional imaging / patient is under follow-up for recurrence monitoring, usally every 3 - 12 months (depending on the severity of the disease).

Sample requirement and Turn Around Time (TAT)
  • 40 ml blood in DCGL and EDTA tubes
  • 8 – 10 working days from receipt of the sample in the laboratory